Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inconsistency of HER2 test raises questions.

× No keyword cloud information.

7 in total

1. HER2/NEU GENE EXPRESSION PRODUCTS EVALUATED WITH SUPERPARAMAGNETIC, GENETICALLY ENGINEERED ANTIBODIES.

Authors: Marek Malecki
Journal: Proc S Dak Acad Sci Date: 2007

2. OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES.

Authors: Marek Malecki; Raf Malecki
Journal: Proc S Dak Acad Sci Date: 2008

3. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.

Authors: Shelly Gunn; I-Tien Yeh; Irina Lytvak; Budi Tirtorahardjo; Natasha Dzidic; Soheila Zadeh; Jaeweon Kim; Chris McCaskill; Lony Lim; Mercedes Gorre; Mansoor Mohammed
Journal: BMC Cancer Date: 2010-07-28 Impact factor: 4.430

4. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.

Authors: Michael Z Gilcrease; Wendy A Woodward; Marlo M Nicolas; Lynda J Corley; Gregory N Fuller; Francisco J Esteva; Susan L Tucker; Thomas A Buchholz
Journal: Am J Surg Pathol Date: 2009-05 Impact factor: 6.394

5. PET of HER2 Expression with a Novel ¹⁸FAl Labeled Affibody.

Authors: Yuping Xu; Zhicheng Bai; Qianhuan Huang; Yunyun Pan; Donghui Pan; Lizhen Wang; Junjie Yan; Xinyu Wang; Runlin Yang; Min Yang
Journal: J Cancer Date: 2017-04-09 Impact factor: 4.207

6. Gadolinium-labeled affibody-XTEN recombinant vector for detection of HER2+ lesions of ovarian cancer lung metastasis using quantitative MRI.

Authors: Alireza Nomani; Geng Li; Siavash Yousefi; Shawn Wu; Obeid M Malekshah; Shahryar K Nikkhoi; Mehrdad Pourfathi; Rahim Rizi; Arash Hatefi
Journal: J Control Release Date: 2021-07-18 Impact factor: 11.467

7. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH).

Authors: Hiroaki Nitta; Beatrice Hauss-Wegrzyniak; Megan Lehrkamp; Adrian E Murillo; Fabien Gaire; Michael Farrell; Eric Walk; Frederique Penault-Llorca; Masafumi Kurosumi; Manfred Dietel; Lin Wang; Margaret Loftus; James Pettay; Raymond R Tubbs; Thomas M Grogan
Journal: Diagn Pathol Date: 2008-10-22 Impact factor: 2.644

7 in total